Treatment Outcomes Between Concurrent Chemoradiotherapy and Combination of Surgery, Radiotherapy, and/or Chemotherapy in Stage III and IV Maxillary Sinus Cancer: Multi-Institutional Retrospective Analysis

Kang, Jung Hun; Cho, Su Hee; Kim, Jin Pyeong; Kang, Ki Mun; Cho, Kyu‐Sup; Kim, Wontaek; Seol, Young Mi; Lee, Suee; Park, Heon Soo; Hur, Won; Choi, Young–Jin; Oh, Sung Yong

doi:10.1016/j.joms.2011.06.221

Cited by 47 publications

(39 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After a median follow-up of 75.6 months, the median PFS was 45.1 months and the 5-year OS 65%. The patients who had undergone surgery had better PFS (hazard ratio 2.363, 95% confidence interval 1.098-5.085, p = 0.028) and OS (hazard ratio 4.989, 95% confidence interval 1.646-15.118, p = 0.004) [31].…”

Section: Concurrent Chemoradiotherapy For Locoregional Diseasementioning

confidence: 97%

The role of systemic therapy in the management of sinonasal cancer: A critical review

Bossi

Saba

Vermorken

et al. 2015

Cancer Treatment Reviews

101

View full text Add to dashboard Cite

Section: Concurrent Chemoradiotherapy For Locoregional Diseasementioning

confidence: 97%

The role of systemic therapy in the management of sinonasal cancer: A critical review

Bossi

Saba

Vermorken

et al. 2015

Cancer Treatment Reviews

101

View full text Add to dashboard Cite

“…Prior studies have reported that a combination of surgery and radiotherapy can provide an improved rate of overall survival (OS), when compared with CRT, for locally advanced paranasal sinus cancer (9,10). Kang et al (11) reported that a combination of surgery and radiotherapy and/or chemotherapy conferred superior five-year OS rates, as compared with CRT, for stage III or localized stage IV maxillary sinus cancer (81.2 vs. 37.9%; log-rank test, P=0.029), which were analyzed using SPSS software version 16.0 (SPSS, Inc., Chicago, IL, USA). The patient in the current report had received a left partial maxillectomy and ipsilateral radical neck lymph node dissection followed by postoperative CRT.…”

Section: Discussionmentioning

confidence: 99%

Recurrent maxillary sinus cancer with only adrenal metastasis

Chang

Hur

Won

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Maxillary sinus cancer is rare, and often presents as a locally advanced disease. Recurrence commonly occurs locoregionally, while fewer patients present with distant metastasis; the most common sites involved are the lung and bone. This report discusses the case of a 64-year-old male who presented with a mass in the left submandibular area. Biopsy was performed and histological analysis identified a poorly differentiated squamous cell carcinoma. After staging work up, it was concluded the patient had a maxillary sinus squamous cell carcinoma at clinical stage IVA. The patient received a left partial maxillectomy and left radical neck dissection followed by postoperative chemoradiotherapy. After three months of CRT, the patient developed a left adrenal gland metastasis without locoregional failure. The patient subsequently received a laparoscopic left adrenalectomy and the results of histological analysis revealed a poorly-differentiated squamous cell carcinoma. Within one month of surgery, the patient had developed multiple metastases at the left adrenalectomy site and succumbed to the disease four months later.

show abstract

“…There have been some studies on concurrent chemoradiation too that have shown benefit [4]. Overall, the reported survival in these studies has been between 34 and 40% at 5 years [2, 4, 23]. A previously published study from our centre by Qureshi et al also reported a 3-year survival rate of 38% [9].…”

Section: Discussionmentioning

confidence: 99%

Induction Chemotherapy in Technically Unresectable Locally Advanced Carcinoma of Maxillary Sinus

Noronha

Patil

Joshi

et al. 2014

Chemotherapy Research and Practice

View full text Add to dashboard Cite

Background. Locally advanced carcinoma of maxillary sinus has been historically reported to have poor prognosis. We evaluated the role of NACT in improving the outcome in these patients. Methods. 41 patients with locally advanced technically unresectable (stage IVa) or unresectable maxillary carcinoma (stage IVb) were treated with induction chemotherapy between 2008 and 2011. The demographic profile, response and toxicity of chemotherapy, definitive treatment received, progression free survival (PFS), and overall survival (OS) were analyzed. Univariate and multivariate analysis were performed to determine factors associated with PFS and OS. Results. The chemotherapy included two drugs (platinum and taxane) in 34 patients (82.9%) and three drugs (platinum, taxane, and 5 FU) in 7 (17.1%). There was no complete response seen in any of the patients, stable disease in 18 (43.9%), partial response in 16 (39%), and progression in 7 (17.1%) patients. After induction, the treatment planned included surgery in 12 (29.3%), CT-RT in 24 (58.5%), radical RT in 1 (2.4%), palliative RT in 1 (2.4%), and palliative chemotherapy in 3 (7.3%) patients. Overall, the median PFS was 10.0 months. The OS at 24 months and 36 months was 41% and 35%, respectively. Conclusion. In unresectable maxillary carcinoma, induction chemotherapy has clinically significant benefit with acceptable toxicity.

show abstract

Treatment Outcomes Between Concurrent Chemoradiotherapy and Combination of Surgery, Radiotherapy, and/or Chemotherapy in Stage III and IV Maxillary Sinus Cancer: Multi-Institutional Retrospective Analysis

Cited by 47 publications

References 32 publications

The role of systemic therapy in the management of sinonasal cancer: A critical review

The role of systemic therapy in the management of sinonasal cancer: A critical review

Recurrent maxillary sinus cancer with only adrenal metastasis

Induction Chemotherapy in Technically Unresectable Locally Advanced Carcinoma of Maxillary Sinus

Contact Info

Product

Resources

About